Did you know that, according to the Parkinson’s Foundation, more than 10 million people worldwide are living with Parkinson’s disease? Here at Ebba Biotech we are constantly in discussions with academics and industries that are actively researching and developing therapies to tackle Parkinson’s disease using our Amytracker product family as a visualisation tool.
One company we would like to highlight is reMYND! The team at reMYND have been utilising the Amytracker 520 variant to enhance their imaging in mice - just look at the images below and hear from reMYND themselves!
“Focusing on the top image, we peer into the injection site (dorsal striatum), where pathogenic fibrils lurk (using DAPI as a nuclear stain). But the story doesn’t end there -as the pathology spreads throughout the mouse brain, it infiltrates crucial regions like the amygdala (lower image). With exceptional precision, Amytracker detects Lewy Bodies and Lewy Neurites, pivotal entities in Parkinson’s disease pathology. Paving the way for quantification of drug efficacy or target engagement studies for our clients.”
We are excited to follow reMYND as they continue to create positive change in the neurodegenerative field. To learn more about their work click here